# TRIUMPH Pivotal Trial

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/triumph-pivotal-trial
Canonical HTML page: https://getbiobrief.com/entity/triumph-pivotal-trial

## Recent coverage (1 stories)

### Laplace TTVR Trial Enrolls 400 Patients After FDA IDE Green Light
2026-07-21 15:55:53 · Sentiment: Bullish · Impact: 7/10 · Sources: 2

Laplace Interventional has obtained FDA IDE approval for its TRIUMPH pivotal trial, targeting 400 patients across 75 sites to test its transcatheter tricuspid valve replacement device. The study includes a 2:1 randomization against commercial TTVR and a 150-patient registry for harder-to-treat patients. Top U.S. cardiologists will lead the trial, building on promising early feasibility data.
Full story: https://getbiobrief.com/story/laplace-fda-ide-triumph-400-patients

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.